NEW YORK, Sept. 3 Reportlinker.com announces that a new market research report is available in its catalogue.
U.S. Markets for Addiction and Substance Abuse Treatment
Advertisement
http://www.reportlinker.com/p0109210/US-Markets-for-Addiction-and-Substance-Abuse-Treatment.html
INTRODUCTION
STUDY GOALS AND OBJECTIVES
Advertisement
This BCC Research report details the complicated world of substance abuse. The increased prevalence of substance abuse poses a threat to the health and welfare of many populations throughout the world. Recreational drugs play a major role in crime and corruption and are becoming a larger problem each year. Abuse of prescription drugs and alcohol places a heavy burden on health resources due to the subsequent medical problems. Breaking the substance abuse cycle is a difficult and tedious process. Pharmaceutical manufacturers have developed several products to assist in recovery from substance abuse. Those products are detailed in the report. Also discussed are the products to help employers, parents, social workers, and other groups and organizations detect for substance abuse.
The objectives of the study are to heighten the awareness of drug abuse and to identify preparations, tests, and important advancements in the drug abuse treatment arena. The study analyzes the new therapeutics and diagnostics for drug abuse treatment from a current standpoint as well as what is on the horizon. Manufacturers of pharmaceutical products have been reluctant to invest valuable time and resources into this market because of the issues facing the market. As a result, the problem of drug abuse continues to grow.
REASONS FOR DOING THE STUDY
This BCC study is presented to increase the awareness of substance abuse and identify pharmaceutical preparations that are used to treat addictions.
INTENDED AUDIENCE
Because of the evolving nature of this important area of medicine, executives of substance abuse pharmaceuticals must remain ever vigilant to the changing environment and strive to keep abreast of new and currently used modalities in all facets of substance abuse treatment
CHAPTER ONE: INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE OF REPORT
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
BCC ONLINE SERVICES
DISCLAIMER
CHAPTER TWO: EXECUTIVE SUMMARY
SUMMARY TABLE U.S. MARKET FOR ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)
SUMMARY FIGURE U.S. MARKET FOR ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS)
CHAPTER THREE: INDUSTRY OVERVIEW
HISTORY OF SUBSTANCE ABUSE
OVERVIEW OF SUBSTANCE ABUSE
OVERVIEW OF SUBSTANCE ABUSE (CONTINUED)
MODELS OF ADDICTION
ADDICTION THEORIES
Biological Theories
Psychological Theories
Sociocultural Theories
PATTERNS OF SUBSTANCE ABUSE
RISK FACTORS
ADDICTIVE PROCESS
DEMOGRAPHIC TRENDS
TABLE 1 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)
FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)
TABLE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)
FIGURE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)
TOBACCO USE
FIGURE 3 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF TOBACCO USE, 2005 (MILLION PEOPLE)
Age
FIGURE 4 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER, 2005 (%)
Gender
FIGURE 5 PAST MONTH OF TOBACCO USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)
Race/Ethnicity
FIGURE 6 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)
Education
FIGURE 7 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2006 (%)
College Students
FIGURE 8 PAST MONTH OF TOBACCO USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18 TO 22, ESTIMATED, 2006 (%)
Employment
FIGURE 9 PAST MONTH OF TOBACCO BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2006 (%)
Geographic Area
FIGURE 10 PAST MONTH OF TOBACCO USE BY GEOGRAPHIC REGION BASED ON POPULATION DENSITY FOR AGES 12 OR OLDER, ESTIMATED, 2006 (%)
Association of Tobacco Use with Illicit Drug and Alcohol
Use
FIGURE 11 PAST MONTH ILLICIT DRUG, ALCOHOL USE AMONG SMOKERS AND NONSMOKERS AGED 12 OR OLDER, ESTIMATED 2006 (%)
ALCOHOL USE
FIGURE 12 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY DRINKING STATUS: UNITED STATES, 1997 AND 2006 (%)
Alcohol Frequency
FIGURE 13 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY FREQUENCY: UNITED STATES, 2002-2005 (%)
Age
FIGURE 14 PAST MONTH ALCOHOL USE AMONG PERSONS BY AGE, 2005 (%)
Gender
FIGURE 15 PAST MONTH ALCOHOL USE FOR MALES AND FEMALES AGE 12 OR OLDER, 2005 (%)
Pregnant Women
FIGURE 16 PAST MONTH OF ALCOHOL USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED 2002-2007 (%)
Race/Ethnicity
FIGURE 17 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)
Education
FIGURE 18 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006 (%)
College Students
FIGURE 19 PAST MONTH ALCOHOL USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2002 AND 2006 (%)
Employment
FIGURE 20 PAST MONTH ALCOHOL USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)
Geographic Area
FIGURE 21 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY UNITED STATES GEOGRAPHIC REGION, 1997 AND 2006 (%)
Driving Under the Influence of Alcohol
FIGURE 22 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ALCOHOL, AGES 12 OR OLDER, ESTIMATED, 2005 AND 2006 (%)
ILLICIT DRUG USE
FIGURE 23 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF DRUG: UNITED STATES, 2002-2005 (%)
FIGURE 23 (CONTINUED)
Age
FIGURE 24 PAST MONTH ILLICIT DRUG USE BY AGE, 2005 (%)
Gender
FIGURE 25 PAST MONTH ILLICIT DRUG USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)
Pregnant Women
FIGURE 26 PAST MONTH ILLICIT DRUG USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED, 2005-2006 (%)
Race/Ethnicity
FIGURE 27 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, ESTIMATED, 2005
Education
FIGURE 28 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006
College Students
FIGURE 29 PAST MONTH ILLICIT DRUG USE BY ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2005-2006 (%)
Employment
FIGURE 30 PAST MONTH ILLICIT DRUG USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)
Geographic Area
FIGURE 31 PAST MONTH ILLICIT DRUG USE FOR GEOGRAPHIC REGION BASED ON POPULATION DENSITY AGES 12 OR OLDER, ESTIMATED, 2005-2006 (%)
Criminal Justice Populations
FIGURE 32 PAST YEAR ILLICIT DRUG USE BY PAROLE AND PROBATION STATUS AGED 18 OR OLDER, ESTIMATED, 2005-2006 (%)
Frequency of Use
Association with Cigarette and Alcohol Use
FIGURE 33 PAST MONTH ALCOHOL AND TOBACCO USE AMONG ILLICIT DRUG USERS AND NON ILLICIT DRUG USERS AGED 12 OR OLDER, ESTIMATED, 2005-2006
Driving Under the Influence of Illicit Drugs
FIGURE 34 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ILLICIT DRUGS, AGES 12 OR OLDER, ESTIMATED, 2005-2006 (MILLIONS)
ADDICTION TREATMENT COSTS SHIFTING
MANAGED CARE IMPACT
PARITY LAW
REIMBURSEMENT ISSUES
TABLE 3 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY, MARCH 31, 2006 (PERCENT DISTRIBUTION)
TABLE 4 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY: MARCH 31, 2006 (PERCENT DISTRIBUTION)
ECONOMIC COSTS OF SUBSTANCE ABUSE
TABLE 5 COMPARISON OF COSTS OF MAJOR HEALTH PROBLEMS IN U.S. ($ BILLIONS)
TABLE 6 ECONOMIC COSTS TO SOCIETY OF DRUG ABUSE 1992-2002 ($ MILLIONS)
STUMBLING BLOCKS TO DRUG ABUSE TREATMENT
NEW AVENUES FOR TREATMENT OF SUBSTANCE ABUSE
TABLE 7 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE--ALCOHOL, COCAINE, MARIJUANA AND HEROIN
TABLE 7 (CONTINUED)
TABLE 8 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE--OTHER OPIATES, PCPS, HALUCINOGENS, AMPHETAMINES, OTHER STIMULANTS, AND TRANQUILIZERS
TABLE 8 (CONTINUED)
TABLE 9 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE--SEDATIVES, INHALANTS, AND OTHER
TABLE 9 (CONTINUED)
TABLE 10 USE OF SUBSTANCES BY AMONG PERSONS AGED 50 OR OLDER, ESTIMATED 1999 AND PROJECTED 2020 BY GENDER, RACE, AND AGE GROUP, 1999
TABLE 11 USE OF SUBSTANCES BY PERSONS AGED 50 OR OLDER, BY GENDER, RACE, AND AGE GROUP, 2020
REGULATORY ISSUES
EFFECTS OF POLY DRUG ABUSE
POLYDRUG USE BY AGE
TABLE 12 ADMISSIONS REPORTING POLYDRUG ABUSE, BY AGE GROUP, 2002
PRIMARY AND SECONDARY USE
THE UNINSURED
TABLE 13 TOP 10 PRINCIPAL DIAGNOSES IN U.S. HOSPITALS WHICH HAVE UNINSURED RATES, 2002
TREATMENT FACILITIES AND PROGRAMS
OWNERSHIP OF SUBSTANCE ABUSE FACILITIES
TABLE 14 FACILITY OPERATION: NUMBER AND PERCENT DISTRIBUTION, 2002-2006
TREATMENT COSTS
TABLE 15 ESTIMATED TOTAL COSTS FOR SUBSTANCE ABUSE TREATMENT AND COST PER ADMISSION, BY TYPE OF CARE: 1997 (INFLATED TO 2002 COST LEVELS)
RESIDENTIAL REHABILITATION PATTERNS
Culture
Antabuse
Basic Methods
SELF-HELP GROUPS
TABLE 16 PERCENT DISTRIBUTION OF PERSONS AGED 12 OR OLDER WHO ATTENDED A "SELF-HELP" GROUP IN THE PAST YEAR BECAUSE OF THEIR ALCOHOL OR ILLICIT DRUG USE AND OF TOTAL POPULATION AGED 12 & OLDER, BY SOCIODEMOGRAPHIC CHARACTERISTICS: 2006 AND 2007
TABLE 16 (CONTINUED)
FIGURE 35 PERCENTAGES OF PAST YEAR SELF-HELP GROUP ATTENDEES AGED 12 OR OLDER, BY SUBSTANCE(S) FOR WHICH THEY ATTENDED A "SELF-HELP" GROUP, 2006 AND 2007 (%)
FIGURE 35 (CONTINUED)
NATIONAL PROGRAMS FOR SUBSTANCE ABUSE
BARRIERS TO MARKET ENTRY
NONACCEPTANCE OF MEDICAL MODELS OF ADDICTION
CHAPTER FOUR: PHARMACEUTICAL PRODUCTS
STIMULANTS
NICOTINE
Characteristics
Effects of Use
Complications
Therapeutic Management
TABLE 17 SMOKING CESSATION PRODUCTS
Therapeutic Management (Continued)
AMPHETAMINES
Characteristics
Effects of Use
Complications
Therapeutic Management
TABLE 18 AMPHETAMINE ABUSE TREATMENTS
COCAINE AND CRACK
Characteristics
Effects of Use
Complications
Therapeutic Management
TABLE 19 COCAINE ABUSE TREATMENTS
OTHER STIMULANTS
DEPRESSANTS
SEDATIVES-HYPNOTICS
Characteristics
Effects of Use
Complications
Therapeutic Management
ALCOHOL
Characteristics
Effects of Use
Complications
Complications (Continued)
Therapeutic Management
TABLE 20 ALCOHOL ABUSE TREATMENTS
OPIATES
Characteristics
Effects of Use
Complications
Therapeutic Management
Methadone
Other Products
Other Products (Continued)
TABLE 21 OPIATE ABUSE TREATMENTS
HALLUCINOGENS
CANNABIS
Characteristics
Effects of Use
Complications
Therapeutic Management
LYSERGIC ACID DIETHYLAMIDE, DIMETHYLTRYPTAMINE, MESCALINE, AND RELATED SUBSTANCES
Characteristics
Characteristics (Continued)
Effects of Use
Therapeutic Management
OTHER HALLUCINOGENS
INHALANTS AND OTHER DRUGS OF ABUSE
Gases, Solvents and Nitrites
Gases, Solvents . . . (Continued)
Anabolic Steroids
DIAGNOSTIC TESTING
URINE TESTING
SALIVA TESTING
BLOOD TESTING
PATCH TESTING
HAIR TESTING
SAMHSA POSITIVE DRUG TEST GUIDELINES
TABLE 22 POSITIVE DRUG TEST GUIDELINES (NG/ML)
DRUG TESTING INDEXES
TABLE 23 ANNUAL POSITIVITY RATES FOR U.S. WORKERS, BY YEAR 1988-2004 (%)
TABLE 24 POSITIVITY RATES FOR U.S. WORKERS BY TESTING REASON, 2000-2004
TABLE 25 POSITIVITY RATES FOR U.S. WORKERS BY DRUG CATEGORY AS A PERCENTAGE OF ALL POSITIVE TESTS (%)
TABLE 25 (CONTINUED)
POINT-OF-CARE SUBSTANCE ABUSE DIAGNOSTIC TESTING
Tobacco Testing
TABLE 26 POINT-OF-CARE NICOTINE DIAGNOSTIC TEST PRODUCTS
Jant Pharmacal
Nymox Pharmaceuticals
Princeton BioMeditech Corporation
Alcohol Testing
TABLE 27 POINT OF CARE ALCOHOL DIAGNOSTIC TEST PRODUCTS
Jant Pharmacal
MEDTOX Scientific, Inc.
OraSure Technologies
Princeton BioMeditech Corporation
Varian, Inc
Drug Testing
TABLE 28 POINT-OF-CARE DRUG DIAGNOSTIC TESTING PRODUCTS
Alfa Scientific Designs
American Bio Medica
BioScan Screening Systems
Biosite Diagnostics
Inverness Medical
MEDTOX Scientific, Inc.
OraSure Technologies
Phamatech
Princeton BioMeditech
Psychemedics Corp.
Varian, Inc
Sun Biomedical
HOME SUBSTANCE ABUSE DIAGNOSTIC TESTING
Alcohol Testing
TABLE 29 ALCOHOL HOME DIAGNOSTIC TESTING PRODUCTS
Jant Pharmacal
Sun Biomedical Laboratories
Drug Testing
TABLE 30 DRUG HOME DIAGNOSTIC TESTING PRODUCTS
Psychemedics
Dr. Brown's (Elan Corporation)
Inverness Medical Innovations, Inc.
Phamatech
Princeton BioMeditech
Psychemedics
Sun Biomedical Laboratories
Sun Biomedical . . . (Continued)
CHAPTER FIVE: MARKET SIZE AND GROWTH
MARKET SIZE AND GROWTH
TABLE 31 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)
FIGURE 36 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS)
PRESCRIPTION AND OVER-THE-COUNTER PHARMACEUTICAL TREATMENTS
SMOKING CESSATION
DRUG AND ALCOHOL ABUSE
TABLE 32 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)
FIGURE 37 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)
DIAGNOSTIC TESTING
POINT-OF-CARE TESTING
HOME TESTING
TABLE 33 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)
FIGURE 38 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, 2006-2013 ($ MILLIONS)
CHAPTER SIX: RESEARCH AND DEVELOPMENT
GOALS
AREAS OF CONCENTRATION
INDUSTRY NEEDS
CURRENT DRUGS IN CLINICAL TRIALS
ALCOHOL TREATMENT
OPIATE TREATMENT
GENERAL ADDICTION
TOBACCO TREATMENT
TABLE 34 SUBSTANCE ABUSE PRODUCTS IN DEVELOPMENT
TABLE 34 (CONTINUED)
MISCELLANEOUS SUBSTANCE ABUSE TREATMENT DISCOVERIES
MISCELLANEOUS SUBSTANCE ABUSE . . .(CONTINUED)
MISCELLANEOUS SUBSTANCE ABUSE . . .(CONTINUED)
CHAPTER SEVEN: INDUSTRY STRUCTURE
MARKET LEADERS
PFIZER
RECKITT BENCKISER
GLAXOSMITHKLINE
NOVARTIS
PSYCHEMEDICS
ORASURE TECHNOLOGIES
TABLE 35 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007
FIGURE 39 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007 (%)
TABLE 36 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007
FIGURE 40 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007 (%)
INDUSTRY PARTICIPANTS BY PRODUCT TYPE
TABLE 37 LEADING SUBSTANCE ABUSE PHARMACEUTICAL TREATMENT AND DIAGNOSTIC TESTING MANUFACTURERS BY PRODUCT TYPE, 2008
TABLE 37 (CONTINUED)
MARKET ANALYSIS
Anti-Depressant Market
Additional Therapies
Opportunities
Opportunities (Continued)
CHAPTER EIGHT: COMPANY PROFILES
GLAXOSMITHKLINE PLC
HISTORY
NOVARTIS PHARMACEUTICALS CORP.
HISTORY
ORASURE TECHNOLOGIES
HISTORY
PFIZER, INC
HISTORY
PHAMATECH, INC.
HISTORY
PSYCHEMEDICS CORP
HISTORY
RECKITT BENCKISER PLC
HISTORY
APPENDIX A--LIST OF COMPANIES
ABBOT DIAGNOSTICS
ABBOTT LABORATORIES
ALFA SCIENTIFIC DESIGNS, INC
ALKERMES, INC.
AMERICAN BIO MEDICA CORPORATION
ARADIGM CORPORATION
BARR LABORATORIES, INC
BIOSCAN SCREENING SYSTEMS, INC.
BIOSITE, INC.
BIOVAIL CORPORATION
BRISTOL-MYERS SQUIBB COMPANY
CARY PHARMACEUTICALS, INC.
CELTIC PHARMA MANAGEMENT L.P.
CEPHALON, INC.
CYTOS BIOTECHNOLOGY AG
DRUG ENFORCEMENT ADMINISTRATION
ELAN CORPORATION, PLC
ELBION NV
ELI LILLY & COMPANY
ENDO PHARMACEUTICALS
FOOD AND DRUG ADMINISTRATION
FOREST LABORATORIES, INC.
GLAXOSMITHKLINE PLC
INVERNESS MEDICAL INNOVATIONS, INC
JANT PHARMACAL CORPORATION
JOHNSON & JOHNSON
JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS (JCAHO)
MALLINCKRODT
MEDTOX SCIENTIFIC, INC.
NABI BIOPHARMACEUTICALS
NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM
NATIONAL INSTITUTE ON DRUG ABUSE
NOVARTIS INTERNATIONAL AG
NOVARTIS PHARMACEUTICALS CORP.
NYMOX PHARMACEUTICAL CORP.
OFFICE OF NATIONAL DRUG CONTROL POLICY
ORASURE TECHNOLOGIES, INC
OVATION PHARMACEUTICALS, INC
PFIZER, INC
PHAMATECH, INC.
PLIVA, INC.
PRINCETON BIOMEDITECH CORP.
PSYCHEMEDICS CORPORATION
PURDUE PHARMA, L.P.
RECKITT-BENCKISER PLC
ROCHE
SANOFI-AVENTIS
SOMAXONE PHARMACEUTICALS, INC
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA)
SUN BIOMEDICAL LABORATORIES, INC.
TITAN PHARMACEUTICALS, INC
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
VALEANT PHARMACEUTICALS INTERNATIONAL
VARIAN, INC
XANODYNE PHARMACEUTICALS, INC
APPENDIX B--LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES
TABLE 38 LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 83 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 38 (CONTINUED)
TABLE 83 (CONTINUED)
TABLE 83 (CONTINUED)
TABLE 83 (CONTINUED)
TABLE 83 (CONTINUED)
TABLE 83 (CONTINUED)
TABLE 83 (CONTINUED)
TABLE 83 (CONTINUED)
LIST OF TABLES
SUMMARY TABLE U.S. MARKET FOR ADDICTION AND SUBSTANCE
ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013
($ MILLIONS)
TABLE 1 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)
TABLE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)
TABLE 3 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY, MARCH 31, 2006 (PERCENT DISTRIBUTION)
TABLE 4 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY: MARCH 31, 2006 (PERCENT DISTRIBUTION)
TABLE 5 COMPARISON OF COSTS OF MAJOR HEALTH PROBLEMS IN U.S. ($ BILLIONS)
TABLE 6 ECONOMIC COSTS TO SOCIETY OF DRUG ABUSE 1992-2002 ($ MILLIONS)
TABLE 7 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE--ALCOHOL, COCAINE, MARIJUANA AND HEROIN
TABLE 8 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE--OTHER OPIATES, PCPS, HALUCINOGENS, AMPHETAMINES, OTHER STIMULANTS, AND TRANQUILIZERS
TABLE 9 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE--SEDATIVES, INHALANTS, AND OTHER
TABLE 10 USE OF SUBSTANCES BY AMONG PERSONS AGED 50 OR OLDER, ESTIMATED 1999 AND PROJECTED 2020 BY GENDER, RACE, AND AGE GROUP, 1999
TABLE 11 USE OF SUBSTANCES BY PERSONS AGED 50 OR OLDER, BY GENDER, RACE, AND AGE GROUP, 2020
TABLE 12 ADMISSIONS REPORTING POLYDRUG ABUSE, BY AGE GROUP, 2002
TABLE 13 TOP 10 PRINCIPAL DIAGNOSES IN U.S. HOSPITALS WHICH HAVE UNINSURED RATES, 2002
TABLE 14 FACILITY OPERATION: NUMBER AND PERCENT DISTRIBUTION, 2002-2006
TABLE 15 ESTIMATED TOTAL COSTS FOR SUBSTANCE ABUSE TREATMENT AND COST PER ADMISSION, BY TYPE OF CARE: 1997 (INFLATED TO 2002 COST LEVELS)
TABLE 16 PERCENT DISTRIBUTION OF PERSONS AGED 12 OR OLDER WHO ATTENDED A "SELF-HELP" GROUP IN THE PAST YEAR BECAUSE OF THEIR ALCOHOL OR ILLICIT DRUG USE AND OF TOTAL POPULATION AGED 12 & OLDER, BY SOCIODEMOGRAPHIC CHARACTERISTICS: 2006 AND 2007
TABLE 17 SMOKING CESSATION PRODUCTS
TABLE 18 AMPHETAMINE ABUSE TREATMENTS
TABLE 19 COCAINE ABUSE TREATMENTS
TABLE 20 ALCOHOL ABUSE TREATMENTS
TABLE 21 OPIATE ABUSE TREATMENTS
TABLE 22 POSITIVE DRUG TEST GUIDELINES (NG/ML)
TABLE 23 ANNUAL POSITIVITY RATES FOR U.S. WORKERS, BY YEAR 1988-2004 (%)
TABLE 24 POSITIVITY RATES FOR U.S. WORKERS BY TESTING REASON, 2000-2004
TABLE 25 POSITIVITY RATES FOR U.S. WORKERS BY DRUG CATEGORY AS A PERCENTAGE OF ALL POSITIVE TESTS (%)
TABLE 26 POINT-OF-CARE NICOTINE DIAGNOSTIC TEST PRODUCTS
TABLE 27 POINT OF CARE ALCOHOL DIAGNOSTIC TEST PRODUCTS
TABLE 28 POINT-OF-CARE DRUG DIAGNOSTIC TESTING PRODUCTS
TABLE 29 ALCOHOL HOME DIAGNOSTIC TESTING PRODUCTS
TABLE 30 DRUG HOME DIAGNOSTIC TESTING PRODUCTS
TABLE 31 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE
ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)
TABLE 32 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 33 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)
TABLE 34 SUBSTANCE ABUSE PRODUCTS IN DEVELOPMENT
TABLE 35 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007
TABLE 36 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007
TABLE 37 LEADING SUBSTANCE ABUSE PHARMACEUTICAL TREATMENT AND DIAGNOSTIC TESTING MANUFACTURERS BY PRODUCT TYPE, 2008
TABLE 38 LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES
LIST OF FIGURES
SUMMARY FIGURE U.S. MARKET FOR ADDICTION AND SUBSTANCE
ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS)
FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)
FIGURE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)
FIGURE 3 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF TOBACCO USE, 2005 (MILLION PEOPLE)
FIGURE 4 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER, 2005 (%)
FIGURE 5 PAST MONTH OF TOBACCO USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)
FIGURE 6 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)
FIGURE 7 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2006 (%)
FIGURE 8 PAST MONTH OF TOBACCO USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18 TO 22, ESTIMATED, 2006 (%)
FIGURE 9 PAST MONTH OF TOBACCO BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2006 (%)
FIGURE 10 PAST MONTH OF TOBACCO USE BY GEOGRAPHIC REGION BASED ON POPULATION DENSITY FOR AGES 12 OR OLDER, ESTIMATED, 2006 (%)
FIGURE 11 PAST MONTH ILLICIT DRUG, ALCOHOL USE AMONG SMOKERS AND NONSMOKERS AGED 12 OR OLDER, ESTIMATED 2006 (%)
FIGURE 12 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY DRINKING STATUS: UNITED STATES, 1997 AND 2006 (%)
FIGURE 13 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY FREQUENCY: UNITED STATES, 2002-2005 (%)
FIGURE 14 PAST MONTH ALCOHOL USE AMONG PERSONS BY AGE, 2005 (%)
FIGURE 15 PAST MONTH ALCOHOL USE FOR MALES AND FEMALES AGE 12 OR OLDER, 2005 (%)
FIGURE 16 PAST MONTH OF ALCOHOL USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED 2002-2007 (%)
FIGURE 17 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)
FIGURE 18 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006 (%)
FIGURE 19 PAST MONTH ALCOHOL USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2002 AND 2006 (%)
FIGURE 20 PAST MONTH ALCOHOL USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)
FIGURE 21 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY UNITED STATES GEOGRAPHIC REGION, 1997 AND 2006 (%)
FIGURE 22 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ALCOHOL, AGES 12 OR OLDER, ESTIMATED, 2005 AND 2006 (%)
FIGURE 23 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF DRUG: UNITED STATES 2002-2005 (%)
FIGURE 24 PAST MONTH ILLICIT DRUG USE BY AGE, 2005 (%)
FIGURE 25 PAST MONTH ILLICIT DRUG USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)
FIGURE 26 PAST MONTH ILLICIT DRUG USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED, 2005-2006 (%)
FIGURE 27 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, ESTIMATED, 2005
FIGURE 28 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006
FIGURE 29 PAST MONTH ILLICIT DRUG USE BY ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2005- 2006 (%)
FIGURE 30 PAST MONTH ILLICIT DRUG USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)
FIGURE 31 PAST MONTH ILLICIT DRUG USE FOR GEOGRAPHIC REGION BASED ON POPULATION DENSITY AGES 12 OR OLDER, ESTIMATED, 2005-2006 (%)
FIGURE 32 PAST YEAR ILLICIT DRUG USE BY PAROLE AND PROBATION STATUS AGED 18 OR OLDER, ESTIMATED, 2005-2006 (%)
FIGURE 33 PAST MONTH ALCOHOL AND TOBACCO USE AMONG ILLICIT DRUG USERS AND NON ILLICIT DRUG USERS AGED 12 OR OLDER, ESTIMATED, 2005-2006
FIGURE 34 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ILLICIT DRUGS, AGES 12 OR OLDER, ESTIMATED, 2005-2006 (MILLIONS)
FIGURE 35 PERCENTAGES OF PAST YEAR SELF-HELP GROUP ATTENDEES AGED 12 OR OLDER, BY SUBSTANCE(S) FOR WHICH THEY ATTENDED A "SELF-HELP" GROUP, 2006 AND 2007 (%)
FIGURE 36 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS) FIGURE 37 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)
FIGURE 38 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, 2006-2013 ($ MILLIONS)
FIGURE 39 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007 (%)
FIGURE 40 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007 (%)
To order this report:
U.S. Markets for Addiction and Substance Abuse Treatment
http://www.reportlinker.com/p0109210/US-Markets-for-Addiction-and-Substance-Abuse-Treatment.html
More market research reports here!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker